Renal Cell Carcinoma

Progression-free survival was significantly improved in treatment-naïve patients with advanced renal cell carcinoma by combining the PD-L1 inhibitor avelumab (Bavencio) with the VEGF inhibitor axitinib (Inlyta) compared with sunitinib, according to findings from the phase III JAVELIN Renal 101 study.

The presence of biomarkers including SDF-1, VEGF-A, and sVEGFR1 and 2 at baseline were associated with poorer progression-free survival and overall survival in patients with metastatic renal cell carcinoma treated with sunitinib prior to nephrectomy.

Daniel J. George, MD, professor of medicine and surgery at Duke Cancer Institute, discusses his rationale for choosing patients with renal cell carcinoma that should receive adjuvant sunitinib therapy. 

Perspective on the Treatment of Advanced Renal Cell Cancer

Treatment of Refractory Metastatic Renal Cell Carcinoma

Timothy M. Kuzel, MD, recently spoke on the treatment decisions and consideration he makes when treating patients with renal cell carcinoma. Kuzel, chief of the Division of Hematology/Oncology, deputy director of Rush Cancer Center, Rush University Medical Center, explained his treatment decisions based on 2 case scenarios during a <em>Targeted Oncology </em>live case-based peer perspectives presentation.

Treatment with pembrolizumab and bevacizumab proved to be a promising combination regimen for&nbsp;patients with metastatic renal cell carcinoma, according to phase Ib/II data presented at the 2018 ASCO Annual Meeting.

Mario Snzol, MD,&nbsp;discusses the latest developments with immunotherapy, which he says is poised to become the standard of care in the treatment of patients with metastatic RCC.

Daniel J. George, MD, professor of medicine and surgery at Duke Cancer Institute, discussed the results from these 2 analyses in this high-risk patient population with RCC compared to metastatic RCC. He also shares his own insights on what to take away from this data.